Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Controlled extension study of canakinumab for treatment and prevention of gout flares
2010-018913-32Phase 3Completed
- Sponsor
- Novartis
- Start
- Jul 2010
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised trial of canakinumab in gout and acute gout flare (2 arms), sponsored by Novartis. Primary endpoint: Long-term safety and tolerability of canakinumab 150 mg s.c. versus triamcinolone acetonide 40 mg i.m. Started Jul 2010; status: completed.
02
Drugs
canakinumab
03
Conditions
goutacute gout flare
Beyond the preview
Go deeper on 2010-018913-32.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2010-018913-32.